Clinical Trial Update: Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Candonilimab combined with all-trans retinoic acid to prevent oral cancer recurrence in patients with oral potentially maligna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Cancer
• Oral Potentially Malignant Disorder

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Candonilimab

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Oral Cavity Cancer, Premalignant Lesion | Phase 2 | Status: ACTIVE_NOT_RECRUITING